Investors & Media Contact Us Linkedin Twitter Who We Are Focus Areas Pipeline Patients Careers Biomarker-Defined Metastatic Solid Tumors Too many loved ones live with uncertainty. Let’s find answers. Precision medicine is transforming how we treat cancer. We know that a patient’s response to treatment can depend on the genetic makeup of their cancer and are applying a precision medicine approach to develop new treatments for a number of highly prevalent, biomarker-defined metastatic cancers. Our ambition is for patients with cancer to lead longer, better lives. Let’s go vertical We are collaborating with BeiGene to take a vertical inhibition approach to the MAPK pathway. A study combining our MEK inhibitor with BeiGene’s RAF dimer inhibitor represents a unique opportunity to treat patients with MAPK-driven cancers, particularly those with RAS mutations, where rational targeted therapies are urgently needed for patients. We believe that through a potent and optimized vertical inhibition combination therapy approach, we may be able to address several biomarker-defined patient subsets within the broader MAPK-mutated solid tumor space. LEARN MORE LEARN MORE LEARN MORE LEARN MORE Linkedin Twitter Who We Are Leadership & Board Mission & Values Partners & Collaborators Focus Areas Rare Oncology BCMA Combinations in Multiple Myeloma Biomarker-Defined Metastatic Solid Tumors Pipeline Nirogacestat Mirdametinib Clinical Trials Investigator-Initiated Research Careers View Opportunities Patients Desmoid Tumors NF1-PN Expanded Access Contact Investors & Media Press Releases Events & Presentations Corporate Governance Financial Information Stock Information Investor Resources © 2021 SpringWorks Therapeutics. All rights reserved. Privacy Policy Terms of Use By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies